NHS Trials of Psychedelic Therapy: Rethinking Depression Treatment

In December 2025, the NHS began clinical trials assessing psilocybin, the psychoactive compound in magic mushrooms, for treatment-resistant depression. This compound may be recognized for its therapeutic potential.

Led by King's College London, the trials involve 216 patients, averaging 42 years old, who have not responded to at least two conventional antidepressants. Psilocybin is administered in controlled settings, with trained therapists guiding patients through sessions lasting up to six hours. Participants often describe their experiences as cathartic. "It was the first time in my life I ever felt a sense of belonging," said Larissa Hope, who credits psilocybin with her recovery from severe depression.

A 2021 meta-analysis in The New England Journal of Medicine found that psilocybin outperformed escitalopram, a common SSRI, in reducing depression severity over six weeks. However, small sample sizes raise questions about long-term efficacy. Critics like Dr. Adrian Bellamy of the Royal College of Psychiatrists caution, "While the immediate results are compelling, we don't yet know how psilocybin compares to existing treatments over a year or more."

Accessibility poses challenges. Each psilocybin therapy session requires individual supervision by a trained therapist, potentially costing over £5,000 ($6,000) per patient. This price far exceeds the NHS's budget for mental health care, complicating the scaling of such interventions.

Regulatory hurdles remain significant. Psilocybin is classified as a Schedule 1 drug under the UK's Misuse of Drugs Regulations 2001, indicating no accepted medical use. Any NHS adoption would necessitate changes in scheduling, prescribing guidelines, and clinician training. "These bureaucratic hurdles are not small," said Dr. Rachel Evans from the University of Manchester. "And they speak to the broader stigma that psychedelics still face within institutional frameworks."

Public perception also plays a critical role. High-profile endorsements, like Prince Harry's mention of psychedelics in his 2023 memoir Spare, have shifted some attitudes. Yet, many remain cautious due to the risk of misuse and the association with recreational drug culture. Past controversies surrounding antidepressants, including withdrawal effects from SSRIs, have left the public skeptical of new treatments.

Proponents argue that psilocybin therapy could address a significant gap in mental health care. Depression affects over 280 million people globally, according to the World Health Organisation, with one-third of patients not achieving remission with conventional treatments. "These are individuals who have been let down by existing options," said Dr. Steve Knowles, a clinical psychologist involved in the trials. "If we can offer them a viable alternative, the ethical imperative is clear."

The NHS trials will continue into late 2026, with interim results expected by mid-year. If successful, they could lead to the integration of psychedelic therapy into mainstream psychiatry, not only in the UK but also internationally. Australia has already approved psilocybin for certain mental health conditions starting in July 2023, becoming the first country to take such a step. Canada and several US states are following suit.

An unresolved issue is equity in access. If psilocybin therapy becomes available but remains costly, it risks becoming a privilege for a select few. The NHS's core principle of universal care may come under strain, highlighting the tension between innovation and affordability in public health systems.

Psilocybin-assisted therapy exists in a complex landscape—balancing hope and skepticism, innovation and practicality. Its future impact on psychiatric care will depend on forthcoming data, discussions, and decisions.